Biologics have revolutionized the treatment of care, but often at high prices. The Biologics Price Competition and Innovation Act (BPCIA) of 2010 created a pathway for approval and market launch of “biosimilar” products with the goal of introducing affordable alternatives and enhancing competition. As the biosimilar market evolves with new biosimilars coming to market, it is essential to consider patient, provider, payer, manufacturer and policy dynamics that influence uptake and affordability.

This panel discussion, led by MILI and Prime Therapeutics leadership, will introduce the biosimilars landscape and discuss coverage and pricing of biosimilars, provider-level factors influencing uptake, legislative challenges, and manufacturer perspectives.